These include: increased expression of growth factor receptors (e.g., EGFR) [25], [26], [27], [35], elevated glucose metabolism and up-regulated glucose transporters (e.g., Glut-1) [23], [24] and an increased tissue proteolysis by the tumor, through upregulation of proteolytic enzymes such as MMP-2, -9 [18], [22], [36] and cathepsin B and D [13], [14]. The gene discussed is SLC2A1; the disease is neoplasm.